BCR-ABL Tyrosine Kinase Inhibitors

Vanflyta (quizartinib)

Quizartinib, sold under the brand name Vanflyta, is a medication used for the treatment of acute myeloid leukemia...Wikipedia

 

 

Manufacturer's Website: Vanflyta                                                                                                                   Average retail cost:   $16,608 /month

Gleevec (imatinib)

Imatinib, sold under the brand names Gleevec among others, is a chemotherapy medication used to treat cancer. Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that is Philadelphia chromosome-positive (Ph+) and certain types of gastrointestinal stromal tumors (GIST), systemic mastocytosis, and myelodysplastic syndrome. It is taken by mouth...Wikipedia

 

 

Manufacturer's Website: Gleevec                                                                                                                    Average retail cost:   $17,104 /month

Sprycel (dasatinib)

Dasatinib is a medication used primarily to treat chronic myelogenous leukemia and selected cases of acute lymphoblastic leukemia. It is produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is a Bcr-Abl (the "Philadelphia chromosome") and Src family tyrosine kinase inhibitor approved for first line use in people with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)...Wikipedia

 

 

Manufacturer's Website: Sprycel                                                                                                                       Average retail cost:   $27,154/month

Tasigna (nilotinib)

Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia...Wikipedia

 

 

Manufacturer's Website: Tasigna                                                                                                                        Average retail cost:   $39,625/month

Bosulif (bosutinib)

Bosutinib (trade name Bosulif) received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March 2013 respectively for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy...Wikipedia

 

Manufacturer's Website: Bosulif                                                                                                                        Average retail cost: *

 

* This drug is only available at select specialty pharmacies, which usually means it may be expensive.

Iclusig (ponatinib)

Ponatinib (trade name Iclusig) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL)...Wikipedia

 

 

Manufacturer's Website: Iclusig                                                                                                                        Average retail cost: *

 

* This drug is only available at select specialty pharmacies, which usually means it may be expensive.

Copyright  2006---2023  Automated Clinical Guidelines, LLC.  All rights reserved.